<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="963">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148611</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-3185D</org_study_id>
    <nct_id>NCT05148611</nct_id>
  </id_info>
  <brief_title>Application Registration Study of ILE in Patients With Acute Poisoning</brief_title>
  <acronym>ILE</acronym>
  <official_title>Application Registration Study of ILE in Patients With Acute Poisoning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Deyang City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Binzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators aimed to study the effect of ILE in the treatment of acute&#xD;
      fat-soluble substance poisoning,to further clarify the relevant mechanism of ILE in the&#xD;
      treatment of fat-soluble drug poisoning,to standardize the relevant procedures of ILE&#xD;
      detoxification treatment and further explore the adverse reactions and coping strategies of&#xD;
      ILE treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fat-soluble drugs refer to drugs that are insoluble in water but soluble in fats and organic&#xD;
      solvents such as carbon tetrachloride, glycerol, oils and other organic solvents. They can&#xD;
      fuse with the phospholipid bilayer of cell membranes, are easily absorbed, and are easier to&#xD;
      pass compared to water-soluble drugs. It is metabolized by the liver, and the metabolites are&#xD;
      excreted by the kidneys, so it has a high clinical use rate. However, in recent years, due to&#xD;
      the improper use of fat-soluble drugs by patients, fat-soluble benzodiazepines sedative and&#xD;
      hypnotic drugs, fat-soluble calcium channel blockers and Î²-blocker drugs, fat-soluble&#xD;
      tricyclic drugs have often occurred. Poisoning such as antidepressants poses a serious threat&#xD;
      to the lives of patients.In addition, organophosphorus pesticides (fat-soluble) have a high&#xD;
      usage rate in China. Severe organophosphorus poisoning can cause multiple organ damages, and&#xD;
      delays in treatment can cause disability or even death. Clinical treatment is mainly based on&#xD;
      routine gastric lavage and oxygen inhalation. Treatment is the mainstay, combined with&#xD;
      medical drugs, hemodialysis, hemoperfusion, etc., and has achieved certain curative effects,&#xD;
      but the mortality rate is still high, so it is of great significance to explore safer and&#xD;
      more effective treatment methods.Intravenous lipid emulsion (ILE) was originally used to&#xD;
      treat overdose of local anesthetics such as bupivacaine, and later also used to treat a&#xD;
      variety of other lipophilic drug poisonings. The research on the treatment of ILE is still in&#xD;
      the preliminary stage and relatively limited. A systematic review of fat emulsions for the&#xD;
      treatment of acute poisoning found that the overall quality of the studies supporting this&#xD;
      treatment is low or very low, but the included case reports indicate that fat emulsions are&#xD;
      effective against verapamil, beta blockers, and certain Tricyclic antidepressants,&#xD;
      bupivacaine, chlorpromazine, and certain antiarrhythmic drugs (eg, flecainide) poisoned&#xD;
      patients have certain benefits. ILE may help treat patients who are hemodynamically unstable&#xD;
      due to poisoning by these drugs.In view of the fact that the research on the treatment of ILE&#xD;
      still needs to be further improved and related adverse reactions need to be further explored&#xD;
      related countermeasures, the investigators plan to launch a registration research program&#xD;
      related to the application of fat emulsion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>mortality rate</measure>
    <time_frame>24 hours</time_frame>
    <description>Patient mortality within 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulatory system</measure>
    <time_frame>24 hours</time_frame>
    <description>Circulation stabilization time: including blood pressure stabilization time, disappearance time of malignant arrhythmia, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>1 week and 28 days</time_frame>
    <description>1 week and 28 days patient mortality</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Poisoning</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Take the patient's blood for general laboratory tests&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        According to the indications of ILE in the treatment of poisoning in clinical toxicology,&#xD;
        the research objects are divided into the following categories:&#xD;
&#xD;
          1. Calcium channel blocker poisoning&#xD;
&#xD;
          2. Beta blocker drug poisoning&#xD;
&#xD;
          3. Tricyclic antidepressant poisoning&#xD;
&#xD;
          4. Organophosphorus (fat-soluble) pesticide poisoning, such as: chlorpyrifos, profenofos,&#xD;
             diazinon, fenthion, phosphaphos, quinalphos, butylpyrimidin, thiazophos, omethoate,&#xD;
             dimethoate Methionine, triazophos, thiomethionine, ethion, sulfoxiphos, imiphos,&#xD;
             fosfoxcarb, pyrifoxaphos, hydrocarbophos, phorate, methyl parathion, parasulfur&#xD;
             Phosphorus, dichlorvos, pyridoxine, etc.&#xD;
&#xD;
          5. Local anesthetic poisoning&#xD;
&#xD;
          6. Poisoning by other fat-soluble substances&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed as acute fat-soluble drug and organophosphorus (fat-soluble) pesticide&#xD;
             poisoning;&#xD;
&#xD;
          2. Conventional treatment is ineffective, especially for patients with circulatory&#xD;
             failure, such as ventricular arrhythmia, shock, cardiac arrest, etc., who need&#xD;
             intravenous fat emulsion treatment;&#xD;
&#xD;
          3. Those who are not allergic to fat milk;&#xD;
&#xD;
          4. Sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mergers with insufficiency of important organs;&#xD;
&#xD;
          2. Patients with malignant tumors;&#xD;
&#xD;
          3. Severe mental disorder affects the treatment;&#xD;
&#xD;
          4. Those with incomplete clinical data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>yi li, Medical PhD</last_name>
    <phone>15098750165</phone>
    <email>qmbb719@163.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute poisoning</keyword>
  <keyword>intravenous lipid emulsion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poisoning</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT05148611/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT05148611/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

